Golden State Equity Partners Buys 12,877 Shares of Haleon plc (NYSE:HLN)

Golden State Equity Partners grew its holdings in shares of Haleon plc (NYSE:HLN) by 342.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 16,633 shares of the company’s stock after buying an additional 12,877 shares during the quarter. Golden State Equity Partners’ holdings in Haleon were worth $159,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of HLN. FMR LLC grew its stake in shares of Haleon by 5.8% during the third quarter. FMR LLC now owns 104,918,269 shares of the company’s stock valued at $1,110,035,000 after buying an additional 5,768,117 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Haleon by 49.9% during the third quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock valued at $96,833,000 after buying an additional 3,046,841 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Haleon by 25.3% during the third quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock valued at $53,791,000 after buying an additional 1,026,939 shares during the last quarter. Natixis Advisors LLC grew its stake in shares of Haleon by 142.5% during the third quarter. Natixis Advisors LLC now owns 1,473,767 shares of the company’s stock valued at $15,593,000 after buying an additional 866,070 shares during the last quarter. Finally, Jane Street Group LLC grew its stake in shares of Haleon by 1,689.4% during the third quarter. Jane Street Group LLC now owns 264,977 shares of the company’s stock valued at $2,803,000 after buying an additional 250,169 shares during the last quarter. Institutional investors own 6.67% of the company’s stock.

Haleon Stock Up 0.6 %

Shares of NYSE HLN opened at $9.54 on Wednesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The firm has a market capitalization of $43.16 billion, a price-to-earnings ratio of 28.04, a PEG ratio of 2.69 and a beta of 0.28. The stock has a 50 day moving average price of $9.54 and a 200 day moving average price of $9.77. Haleon plc has a 52-week low of $7.89 and a 52-week high of $10.80.

Analyst Ratings Changes

HLN has been the topic of a number of analyst reports. Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Morgan Stanley lowered Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.